Moxetumomab pasudotox is a monoclonal antibody-drug conjugate that is used to treat adults with hairy cell leukemia (HCL). It is a type of targeted therapy that works by delivering a cell-killing substance directly to the cancer cells. The medication is made up of a monoclonal antibody (moxetumomab pasudotox-tdfk) that is attached to the cell-killing agent, calicheamicin. The monoclonal antibody binds to a specific protein found on the surface of hairy cell leukemia cells, and when it binds, it delivers the calicheamicin directly to the cancer cells, killing them. Moxetumomab pasudotox is given as an intravenous (IV) infusion and is usually given in combination with other treatments, such as chemotherapy or a stem cell transplant.
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is a medication used to treat adults with a specific type of blood cancer called relapsed or refractory hairy cell leukemia (HCL). This medication is typically only given after other treatments have failed.
Here's a summary of its characteristics:
- Type: CD22-directed cytotoxin Wikipedia: en.wikipedia.org/wiki/Moxetumomab_pasudotox
- Mechanism of action: It binds to a protein (CD22) found on the surface of hairy cells and delivers a toxin that kills the cells https://www.cancer.gov/publications/dictionaries/cancer-drug/def/moxetumomab-pasudotox
- Uses: Treatment for adults with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog Wikipedia: en.wikipedia.org/wiki/Moxetumomab_pasudotox
- Common side effects: Infusion-related reactions, swelling caused by excess fluid in body tissue (edema), nausea, fatigue, headache, fever, constipation, anemia, and diarrhea Wikipedia: en.wikipedia.org/wiki/Moxetumomab_pasudotox
Important Note: Moxetumomab pasudotox is a complex medication and should only be used under the supervision of a qualified healthcare professional.
Here are some additional details to consider:
- Moxetumomab pasudotox is a relatively new medication, having been approved by the FDA in 2018 Wikipedia: en.wikipedia.org/wiki/Moxetumomab_pasudotox.
- It is important to note that this medication can cause serious side effects, and patients should be closely monitored by their doctor while being treated with it https://www.cancer.gov/publications/dictionaries/cancer-drug/def/moxetumomab-pasudotox.